MK-8776 + Cytarabine

Phase 1Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelogenous Leukemia, Acute

Conditions

Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase

Trial Timeline

Jul 29, 2009 → Jun 13, 2011

NCT ID

NCT00907517

About MK-8776 + Cytarabine

MK-8776 + Cytarabine is a phase 1 stage product being developed by Merck for Myelogenous Leukemia, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT00907517. Target conditions include Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.

What happened to similar drugs?

8 of 20 similar drugs in Myelogenous Leukemia, Acute were approved

Approved (8) Terminated (1) Active (11)

✅micafungin + posaconazoleAstellas PharmaApproved

✅NilotinibNovartisApproved

✅imatinib mesylateNovartisApproved

✅NilotinibNovartisApproved

🔄NilotinibNovartisPhase 3

🔄nilotinib + imatinibNovartisPhase 3

🔄imatinib mesilate + interferon-alpha (INF-a) + cytarabine (ARA-C)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00907517	Phase 1	Terminated	Jul 29, 2009	Jun 13, 2011	Myelogenous Leukemia, Acute

Competing Products

20 competing products in Myelogenous Leukemia, Acute

See all competitors

Product	Company	Stage	Hype Score
Bisantrene	Race Oncology	Phase 2	29
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	25
Milademetan + AZA + Milademetan	Daiichi Sankyo	Phase 1	21
micafungin + posaconazole	Astellas Pharma	Approved	43
decitabine Induction Chemotherapy + Induction Chemotherapy	Eisai	Phase 2	27
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine	Eisai	Phase 2	35
Decitabine + Gemtuzumab ozogamicin	Eisai	Phase 2	35
Ondansetron + Palonosetron	Eisai	Phase 2	35
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine + Decitabine	Eisai	Phase 2	27
Decitabine	Eisai	Phase 2/3	38
KW-2449	Kyowa Kirin	Phase 1	21
KW-2449	Kyowa Kirin	Phase 1	21
flumatinib + imatinib	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199	AbbVie	Phase 2	35
Posaconazole + ABT-199 + Decitabine + Azacitidine	AbbVie	Phase 1	21
Venetoclax + Cytarabine	AbbVie	Phase 1/2	32
AZD4877	AstraZeneca	Phase 1	21
MK0457	Merck	Phase 1	29